2E,6E-farnesol

2e,6e-farnesol is a lipid of Prenol Lipids (PR) class. 2e,6e-farnesol is associated with abnormalities such as Granulomatous Disease, Chronic, pathologic fistula and Cavitation. The involved functions are known as Regulation, Metabolic Inhibition, cholesterol biosynthetic process, Process and Transcription, Genetic. 2e,6e-farnesol often locates in Plasma membrane, Cytoplasmic matrix, cornified envelope, Epidermis and peroxisome. The associated genes with 2E,6E-farnesol are RAB3A gene, FOSL1 gene, CASP8AP2 gene, RCC1 gene and GALE gene. The related lipids are Sterols, Membrane Lipids and Steroids.

Cross Reference

Introduction

To understand associated biological information of 2E,6E-farnesol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2E,6E-farnesol?

2E,6E-farnesol is suspected in Granulomatous Disease, Chronic, pathologic fistula and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2E,6E-farnesol

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Per page 10 20 50 | Total 42

PubChem Associated disorders and diseases

What pathways are associated with 2E,6E-farnesol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2E,6E-farnesol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2E,6E-farnesol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2E,6E-farnesol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2E,6E-farnesol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2E,6E-farnesol?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with 2E,6E-farnesol

Download all related citations
Per page 10 20 50 100 | Total 950
Authors Title Published Journal PubMed Link
Lin HP et al. Localization of isoprenylated antigen of hepatitis delta virus by anti-farnesyl antibodies. 1999 J. Gen. Virol. pmid:9934689
Weissmann N et al. Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. 1999 Am. J. Physiol. pmid:9887060
Niv H et al. Membrane interactions of a constitutively active GFP-Ki-Ras 4B and their role in signaling. Evidence from lateral mobility studies. 1999 J. Biol. Chem. pmid:9880539
Fisher JE et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:9874784
Shipman CM et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. 1998 Cancer Res. pmid:9850051
Strickland CL et al. Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. 1998 Biochemistry pmid:9843427
Laezza C et al. v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. 1998 Proc. Natl. Acad. Sci. U.S.A. pmid:9811854
Fioravanti CF and MacInnis AJ The in vitro effects of farnesol and derivatives on Hymenolepis diminuta. 1976 J. Parasitol. pmid:978365
Ferdinandy P et al. Rapid pacing-induced preconditioning is recaptured by farnesol treatment in hearts of cholesterol-fed rats: role of polyprenyl derivatives and nitric oxide. 1998 Mol. Cell. Biochem. pmid:9774182
Pei ZM et al. Role of farnesyltransferase in ABA regulation of guard cell anion channels and plant water loss. 1998 Science pmid:9765153
Miquel K et al. Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. 1998 J. Biol. Chem. pmid:9748300
Aboushadi N and Krisans SK Analysis of isoprenoid biosynthesis in peroxisomal-deficient Pex2 CHO cell lines. 1998 J. Lipid Res. pmid:9741690
Machida K et al. Farnesol-induced generation of reactive oxygen species via indirect inhibition of the mitochondrial electron transport chain in the yeast Saccharomyces cerevisiae. 1998 J. Bacteriol. pmid:9721283
Szilvassy Z et al. Improvement of nitrergic relaxation by farnesol of the sphincter of Oddi from hypercholesterolaemic rabbits. 1998 Eur. J. Pharmacol. pmid:9721042
Nishio E et al. Alpha1-adrenoreceptor stimulation causes vascular smooth muscle cell hypertrophy: a possible role for isoprenoid intermediates. 1998 Eur. J. Pharmacol. pmid:9650858
Vaidya S et al. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. 1998 Arch. Biochem. Biophys. pmid:9647670
Bentinger M et al. Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase. 1998 Arch. Biochem. Biophys. pmid:9606952
Crick DC et al. Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. 1998 J. Neurochem. pmid:9603204
Rubins JB et al. Lovastatin induces apoptosis in malignant mesothelioma cells. 1998 Am. J. Respir. Crit. Care Med. pmid:9603146
Pérez-Sala D et al. Analogs of farnesylcysteine induce apoptosis in HL-60 cells. 1998 FEBS Lett. pmid:9600259
Llorente-Cortés V et al. Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. 1998 Arterioscler. Thromb. Vasc. Biol. pmid:9598832
Hampton RY Genetic analysis of hydroxymethylglutaryl-coenzyme A reductase regulated degradation. 1998 Curr. Opin. Lipidol. pmid:9559264
Aharonson Z et al. Stringent structural requirements for anti-Ras activity of S-prenyl analogues. 1998 Biochim. Biophys. Acta pmid:9545527
Desrosiers RR and Béliveau R Regulation by GTPgammaS of protein carboxylmethyltransferase activity in kidney brush border membranes. 1998 Arch. Biochem. Biophys. pmid:9514644
Ura H et al. Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. 1998 Mol. Carcinog. pmid:9496909
Rajab MS et al. Antimycobacterial activity of (E)-phytol and derivatives: a preliminary structure-activity study. 1998 Planta Med. pmid:9491760
Roullet JB et al. Inhibition of Ca2+ uptake into A7r5 vascular smooth muscle cells by farnesol: lack of effect on membrane fluidity and Ca2+-ATPase activities. 1997 J. Hypertens. pmid:9488229
Haklai R et al. Dislodgment and accelerated degradation of Ras. 1998 Biochemistry pmid:9477957
Hohl RJ et al. Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids. 1998 Lipids pmid:9470172
Iazlovitskaia EM et al. Human leukemia CEM C-1 cells possess a high affinity binding site for farnesol. 1997 Mar-Apr Ukr. Biokhim. Zh. pmid:9463231
Kogo Y and kato J [Malignant tumor and apoptosis]. 1997 Nippon Naika Gakkai Zasshi pmid:9410963
Roullet JB et al. Farnesol inhibits L-type Ca2+ channels in vascular smooth muscle cells. 1997 J. Biol. Chem. pmid:9405427
Ghosh PM et al. Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. 1997 Biochim. Biophys. Acta pmid:9398081
Goossens A and Merckx L Allergic contact dermatitis from farnesol in a deodorant. 1997 Contact Derm. pmid:9385513
Gana-Weisz M et al. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation. 1997 Biochem. Biophys. Res. Commun. pmid:9367867
Noonan DJ and O'Brien ML A hypothetical mechanism for fat-induced rodent hepatocarcinogenesis. 1997 Adv. Exp. Med. Biol. pmid:9361820
Verzár-Petri G et al. [Determination of the composition of camomile oil]. 1976 Pharmazie pmid:935231
Andres DA et al. Expression cloning of a novel farnesylated protein, RDJ2, encoding a DnaJ protein homologue. 1997 Arch. Biochem. Biophys. pmid:9328291
Saisho Y et al. Determination of farnesyl pyrophosphate in dog and human plasma by high-performance liquid chromatography with fluorescence detection. 1997 Anal. Biochem. pmid:9324945
Nozawa Y et al. Stachybotrin C and parvisporin, novel neuritogenic compounds. II. Structure determination. 1997 J. Antibiot. pmid:9315075
Van Dessel G et al. Internalisation of short-chain isoprenyl diphosphates by chromaffin cells from bovine adrenal medulla. 1997 Biochem. Biophys. Res. Commun. pmid:9299441
Crick DC et al. Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. 1997 Biochem. Biophys. Res. Commun. pmid:9299388
Takaichi S et al. The major carotenoid in all known species of heliobacteria is the C30 carotenoid 4,4'-diaponeurosporene, not neurosporene. 1997 Arch. Microbiol. pmid:9297464
Zhang L et al. Isolation and characterization of a prenylcysteine lyase from bovine brain. 1997 J. Biol. Chem. pmid:9287348
Meigs TE and Simoni RD Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. 1997 Arch. Biochem. Biophys. pmid:9281305
Blazer-Yost BL et al. Protein prenylation is required for aldosterone-stimulated Na+ transport. 1997 Am. J. Physiol. pmid:9227422
Flint OP et al. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. 1997 Toxicol. Appl. Pharmacol. pmid:9221828
Leitner JW et al. Hyperinsulinemia potentiates activation of p21Ras by growth factors. 1997 Endocrinology pmid:9112423
Crick DC et al. Geranylgeraniol promotes entry of UT-2 cells into the cell cycle in the absence of mevalonate. 1997 Exp. Cell Res. pmid:9087171
Bostedor RG et al. Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. 1997 J. Biol. Chem. pmid:9083051